Macquarie Group

Macquarie Group’s Spero Therapeutics SPRO Stock Holding History

Macquarie Group’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,100	Closed	-$7K	–	1995
2018 Q4	$7K	Buy	+1,100	New	+$8.91K	﹤0.01%	2006

Other funds holding SPRO

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group's SPRO Position: Q1 2019 in Review

Macquarie Group sold out of Spero Therapeutics (SPRO) in Q1 2019, closing a stake of 1,100 shares — an estimated $7K sold.

Macquarie Group first reported a position in SPRO in Q4 2018 and held it in 1 quarter. The position peaked at $7K in Q4 2018. 55 funds tracked by Wall St. Rank hold SPRO as of Q1 2019.

Macquarie Group reported no remaining Spero Therapeutics position as of Q1 2019 after selling out during the quarter.
Macquarie Group sold 1,100 Spero Therapeutics shares in Q1 2019, an estimated $7K.
Macquarie Group first reported a position in Spero Therapeutics in Q4 2018 and held it in 1 quarter.
Macquarie Group's Spero Therapeutics position peaked at $7K in Q4 2018.
55 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.